Tobacco use disorder therapy reference (2026)

Tobacco use disorder therapy in 2026 organises around three components combined for best outcomes.

Pharmacotherapy.

Nicotine replacement therapy: patches, gum, lozenges, inhaler, nasal spray. Often combined (patch plus short-acting form) for higher efficacy. Available without prescription in many jurisdictions.

Varenicline: oral medicine that partially activates nicotine receptors, reducing both withdrawal symptoms and the rewarding effects of smoking. The most-effective single agent in most studies. Course is typically 12 weeks, longer in selected patients.

Bupropion: oral medicine with effects on dopamine and norepinephrine signalling, reduces cravings and withdrawal. Useful for patients with comorbid depression.

Cytisine: oral medicine related to varenicline, with comparable efficacy at substantially lower cost. Increasingly available in markets including Eastern Europe, the United Kingdom, and additional jurisdictions.

Behavioural support: counselling (in-person or by telehealth), quitlines, structured group programs. Behavioural support roughly doubles the success rate of pharmacotherapy used alone.

Integrated care delivery: primary-care embedded tobacco treatment, telehealth-delivered combined behavioural and pharmacological treatment, employer-sponsored programs. The infrastructure question is the rate-limiting step in capturing the addressable population; many smokers who would benefit from tobacco-use-disorder treatment never engage formal care.

Emerging tier: novel nicotine receptor pharmacotherapy programs are in late-stage trials with the proposition of additional efficacy beyond varenicline.